<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914394</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-310708</org_study_id>
    <nct_id>NCT00914394</nct_id>
  </id_info>
  <brief_title>Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Experimental Increase of Intraocular Pressure in Healthy Humans</brief_title>
  <official_title>Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Experimental Increase of Intraocular Pressure in Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoregulation is defined as the ability of a vascular bed to adapt its vascular resistance
      to changes in perfusion pressure. In the eye, several studies have reported that retinal
      blood flow is autoregulated over a wide range of ocular perfusion pressures. Large scale
      studies have shown that reduced ocular perfusion pressure is an important risk factor for the
      prevalence, the incidence and the progression of primary open angle glaucoma.

      Former studies that investigated ocular blood flow autoregulation focused mainly on choroidal
      blood flow. For the optic nerve head only few data are available, although it seems likely
      that it underlies similar autoregulatory mechanisms.

      A previous study investigating choroidal blood flow has shown that nitric oxide (NO) plays a
      key role in choroidal autoregulation. The present study is designed to test the hypothesis
      that NO plays a role in optic nerve head autoregulation during increased intraocular pressure
      (IOP). Therefore, IOP will be experimentally increased using a suction cup device in the
      absence of presence of either a nitric oxide synthase inhibitor (L-NMMA), an α-receptor
      agonist (phenylephrine) or placebo. Optic nerve head blood flow will be continuously measured
      during the procedure.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>optic nerve head pressure-flow relationship</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NG-monomethyl-L-arginine (L-NMMA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiological saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NG-monomethyl-L-arginine (L-NMMA)</intervention_name>
    <description>bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes</description>
    <arm_group_label>NG-monomethyl-L-arginine (L-NMMA)</arm_group_label>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Physiological saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>1µg/kg/min, infusion period 20 minutes</description>
    <arm_group_label>NG-monomethyl-L-arginine (L-NMMA)</arm_group_label>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Physiological saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological saline solution (as placebo)</intervention_name>
    <description>infusion period 20 minutes</description>
    <arm_group_label>NG-monomethyl-L-arginine (L-NMMA)</arm_group_label>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Physiological saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser Doppler Flowmetry</intervention_name>
    <description>Measurements will be performed at the neuroretinal rim to assess ONH blood flow.</description>
    <arm_group_label>NG-monomethyl-L-arginine (L-NMMA)</arm_group_label>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Physiological saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Goldmann applanation tonometer</intervention_name>
    <description>intraocular pressure measurements</description>
    <arm_group_label>NG-monomethyl-L-arginine (L-NMMA)</arm_group_label>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Physiological saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suction cup</intervention_name>
    <description>Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.</description>
    <arm_group_label>NG-monomethyl-L-arginine (L-NMMA)</arm_group_label>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Physiological saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged between 18 and 35 years, nonsmokers

          -  Men and women will be included in equal parts

          -  Normal findings in the medical history and physical examination unless the
             investigator considers an abnormality to be clinically irrelevant

          -  Normal findings in the laboratory testings unless the investigator considers an
             abnormality to be clinically irrelevant

          -  Normal ophthalmic findings, ametropia less than 1 diopter

        Exclusion Criteria:

          -  Regular use of medication, abuse of alcoholic beverages, participation in a clinical
             trial in the 3 weeks preceding the study

          -  Treatment in the previous 3 weeks with any drug (except intake of oral contraceptives)

          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day

          -  History or presence of gastrointestinal, liver or kidney disease, or other conditions
             known to interfere with distribution, metabolism or excretion of study drugs

          -  Blood donation during the previous 3 weeks

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriele Fuchsjaeger-Mayrl, MD, Univ.Doz.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc Prof Priv-Doz Dr</investigator_title>
  </responsible_party>
  <keyword>L-NG-Monomethyl Arginine</keyword>
  <keyword>Optic Nerve Head Blood Flow</keyword>
  <keyword>Intraocular Pressure</keyword>
  <keyword>Regional Blood Flow</keyword>
  <keyword>Ocular Physiology</keyword>
  <keyword>Optic Disk</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>omega-N-Methylarginine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

